An Alzheimer’s Disease Diagnostic Company
Providing healthcare professionals with the necessary scientific data to identify Alzheimer’s Disease and distinguish it from other dementias - because being in doubt is simply not acceptable.
In over 30 years of research at the National Institute of Health (NIH) and then over a decade of clinical studies at the Rockefeller Neuroscience Institute, we developed THE WORLD'S ONLY GOLD STANDARD VALIDATED TEST FOR IDENTIFYING & DISTINGUISHING ALZHEIMER'S DISEASE FROM OTHER FORMS OF DEMENTIA
The Problem
500K
New dementia cases in the US annually
5.5MM
People in the US afflicted by AD, expected to rise substantially in the coming years with an aging population
$12B
Global AD diagnostics industry is anticipated to grow to a $12B market by 2022
$355B
The annual US healthcare cost of AD and other forms of dementia in 2020
The importance of an early diagnosis:
Timely diagnosis of dementia is important in improving patient outcomes.
Early diagnosis of dementia may have implications for mitigating safety risks, prevention of complications, and patient/family planning for the future.
Upon approval of a disease modifying therapy, accurate and timely diagnostics will be key in managing appropriate access to therapies with the potential to impact healthcare expenditures for costly drug therapies.
Projected number of people age 65 and older (total and by age) in the U.S. population with Alzheimer's dementia, 2010 to 2050.
SYNAPS Dx is a proud member of
The latest news from SYNAPS Dx.
Contact us.
info@synapsdx.com
12358 Parklawn Dr,
Rockville, MD 20852